X4 Pharmaceuticals Announces Major Stock Offering
BOSTON — X4 Pharmaceuticals (NASDAQ: XFOR), a leader in the development of innovative treatments for rare hematology diseases, recently announced a substantial public offering. The company aims to raise approximately $135 million through the sale of 45,860,000 shares of common stock priced at $2.90 per share. Additionally, pre-funded warrants to purchase up to 700,000 shares are also available at $2.899 each. These warrants come with a minimal exercise price of just $0.001, allowing them to be exercised immediately.
Purpose of the Offering
The proceeds from this offering are poised to support the pivotal Phase 3 development of mavorixafor, targeted towards certain chronic neutropenic disorders. These funds will also be allocated for various corporate needs, including general administrative expenses, capital investments, and enhancements to working capital.
Closing and Underwriters
The offering is anticipated to close soon, pending customary closing conditions. The underwriting team includes significant players such as Leerink Partners, Stifel, and Guggenheim Securities, who are joint bookrunning managers for the offering.
Registration and Regulatory Compliance
In compliance with regulations, a registration statement for these securities was previously filed with the Securities and Exchange Commission (SEC). This ensures that the offering aligns with required legal frameworks and investor protections.
Accessing Offering Documents
Investors interested in this offering can access the preliminary prospectus and the final prospectus, which will detail more information about the offering. These documents will be available on the SEC’s website or can be obtained directly from the underwriters' departments.
About X4 Pharmaceuticals
X4 Pharmaceuticals is committed to enhancing the quality of life for patients affected by rare hematology conditions. With a robust development pipeline, the Company has successfully introduced mavorixafor, an innovative CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI®. This treatment addresses significant unmet needs and is undergoing extensive trials, including a pivotal Phase 3 clinical trial known as 4WARD, focused on specific chronic neutropenic disorders.
Innovative Therapies for Rare Diseases
The company's dedication to patients with rare hematology diseases drives its mission forward. By harnessing the expertise surrounding CXCR4, X4 Pharmaceuticals remains at the forefront of developing new therapeutic solutions.
Frequently Asked Questions
1. What is the purpose of X4 Pharmaceuticals' recent stock offering?
The stock offering is aimed at raising funds to advance the pivotal Phase 3 development of mavorixafor and to support general corporate needs.
2. How many shares are being offered in this public offering?
X4 Pharmaceuticals is offering 45,860,000 shares of its common stock and pre-funded warrants for up to 700,000 shares.
3. Who are the underwriters for this offering?
The underwriters include Leerink Partners, Stifel, and Guggenheim Securities, who are acting as joint bookrunning managers.
4. What is mavorixafor, and why is it important?
Mavorixafor is an oral CXCR4 antagonist that provides therapeutic options for patients with chronic neutropenic disorders, addressing significant unmet medical needs.
5. How can investors access the offering documents?
Investment documents, including the preliminary and final prospectus, will be available on the SEC's website as well as through the underwriters' contact departments.
